Unique ID issued by UMIN | UMIN000047191 |
---|---|
Receipt number | R000053831 |
Scientific Title | Management and Treatment for Radiation-Induced Colitis |
Date of disclosure of the study information | 2022/03/22 |
Last modified on | 2022/03/17 14:08:05 |
Management and Treatment for Radiation-Induced Colitis
MATRICS
Management and Treatment for Radiation-Induced Colitis
MATRICS
Japan |
Locally recurrent colorectal cancer
Gastrointestinal surgery |
Malignancy
NO
The aim of this study is to clarify the frequency and severity of radiation-induced colitis that occurs after heavy ion therapy in patients with locally recurrent colorectal cancer with a high degree of proximity or invasion of the tumor to the gastrointestinal tract.
Based on the appropriate endoscopic observation and evaluation of the colitis, we evaluate the safety of surgical treatment for those cases in which it is indicated.
Safety,Efficacy
The frequency and severity of radiation-induced colitis that occurs within two years after heavy ion therapy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Other |
Heavy-ion radiation therapy 73.6Gy/16fr/4weeks
20 | years-old | <= |
Not applicable |
Male and Female
1) Locally recurrent colorectal diseases.
2) Tumor invades or is in close proximity to the gastrointestinal tract, and the site can be observed by colonoscopy.
3) The tumor is not indicated for curative resection.
4) Surgeons at the collaborating institution have previously evaluated that resection of the damaged gastrointestinal tract is feasible.
5) The patient has no distant metastases or has only metastatic lesions that are scheduled for resection.
6) Be at least 20 years of age at the time of enrollment.
7) Patient has a performance status (ECOG) of 0-1.
8) Main organ function is preserved.
9) Written consent for participation in this study has been obtained from the patient.
1) Patients who are considered to be unable to undergo the prescribed hospital visits and examinations.
2) Patients who are receiving chemotherapy or who have not completed chemotherapy within 2 weeks of the start of irradiation.
3) Patients with open wounds or active, refractory infections in the irradiated area.
4) Patients have active multiple cancers.
5) Patients with serious complications.
6) Patients with mental illness or psychiatric symptoms that would make participation in the clinical research difficult or adults who are incapable of consenting.
(7) Patients who are considered to be unsuitable for enrollment in this study by the physician.
6
1st name | Hirotoshi |
Middle name | |
Last name | Takiyama |
National Institutes for Quantum Science and Technology
QST Hospital
263-8555
4-9-1 Anagawa, Inage, Chiba City, Chiba Pref.
0432063306
takiyama.hirotoshi@qst.go.jp
1st name | Hirotoshi |
Middle name | |
Last name | Takiyama |
National Institutes for Quantum Science and Technology
QST Hospital
263-8555
4-9-1 Anagawa, Inage, Chiba City, Chiba Pref.
0432063306
takiyama.hirotoshi@qst.go.jp
National Institutes for Quantum Science and Technology
National Institutes for Quantum Science and Technology
Other
National Institutes for Quantum Science and Technology Certified Review Board
4-9-1 Anagawa, Inage, Chiba City, Chiba Pref.
043-206-4706
helsinki@qst.go.jp
NO
国立国際医療研究センター病院
2022 | Year | 03 | Month | 22 | Day |
Unpublished
Enrolling by invitation
2021 | Year | 11 | Month | 24 | Day |
2022 | Year | 03 | Month | 11 | Day |
2022 | Year | 03 | Month | 22 | Day |
2024 | Year | 12 | Month | 31 | Day |
2022 | Year | 03 | Month | 17 | Day |
2022 | Year | 03 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053831